ELN Frontiers Meeting 2013

From October 11 to 13, the ELN Frontiers Meeting 2013 takes place in Prague, Czech Republic. This year, the focus is on myeloid neoplasms. Abstracts may be submitted until August 31.

Publications from the Network (selected)

Acute lymphoblastic leukemia


Acute myeloid leukemia


Acute myeloid leukemia/myelodysplastic syndromes

- Martino R et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow

Chronic myeloid leukemia


Efficace F et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013 Jul;27(7):1511-9.


Chronic lymphocytic leukemia


Myelodysplastic syndromes


Myeloproliferative neoplasms


**Stem cell transplantation**


**Supportive care**


**Miscellaneous**


### New trials in the ELTR

**CLBH589G2101**  A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)

**ENESTPath**  A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300 mg BID

**ENESTop**  A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib

**CLDE225X2203**  A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients With Acute Leukemia